5-Year HIV Remission Achieved After Sibling Stem Cell Transplant: Key Findings from the Oslo Patient Case

Introduction

A man in Norway has achieved long-term HIV remission—a functional cure—five years after undergoing a stem cell transplant to treat myelodysplastic syndrome, a bone marrow disorder. His case, published in the journal Nature Microbiology, marks the first time HIV remission has been documented after a transplant from a sibling donor. The achievement adds to a small but instructive group of patients worldwide who have eliminated detectable HIV following stem cell transplants, offering scientists new clues about how to attack the virus’s hidden reservoirs. While the procedure carries life-threatening risks and is not a practical cure for the vast majority of the estimated 1.2 million people living with HIV in the United States and 40 million globally, each case helps researchers understand the intricate interplay of genetics, immune response, and medication that can converge to wipe out HIV.

Background: The Elusive Quest for an HIV Cure

HIV infects and destroys key immune cells, primarily CD4 T cells, and can persist in a latent state within cellular reservoirs throughout the body, including in the gut, lymph nodes, and bone marrow. Antiretroviral therapy (ART) can suppress the virus to undetectable levels, restoring immune function and eliminating the risk of sexual transmission, but it cannot eradicate these reservoirs. When ART is stopped, the virus usually rebounds within weeks. A true cure—either complete eradication or long-term remission without ongoing treatment—has remained a holy grail in HIV research.

Over the past two decades, a handful of individuals have achieved sustained HIV remission after receiving allogeneic hematopoietic stem cell transplants (HSCT) to treat an unrelated cancer or hematologic condition. The first and most famous was Timothy Ray Brown, the “Berlin patient,” who in 2008 was declared cured after a transplant from a donor with two copies of the CCR5Δ32 mutation. This mutation prevents the expression of the CCR5 receptor on immune cells, the main entry point used by the most common HIV variant. Since then, other individuals—including the London, New York, and Geneva patients—have been reported in remission. The Oslo patient now joins this exclusive group, but with the novel feature of a sibling donor, which may have implications for understanding compatibility and immune dynamics.

The Evidence: Inside the Oslo Patient Case

The case report was published in 2026 in Nature Microbiology by a research team whose names were not disclosed in the initial reporting, a common practice when privacy concerns are paramount. The single patient is a 63-year-old man diagnosed with HIV who later developed myelodysplastic syndrome, a condition that can progress to leukemia. His treatment team decided to perform an HSCT, using stem cells from his brother, who happened to carry two copies of the CCR5Δ32 mutation (homozygous). Before the transplant, the patient underwent chemotherapy to destroy his existing bone marrow and immune system, a process that drastically reduces the HIV reservoir. Then, he received the donor stem cells to rebuild a new, HIV-resistant immune system.

Five years after the transplant, the researchers conducted exhaustive testing. They analyzed blood samples, gut tissue biopsies, and bone marrow aspirates—some of the most difficult-to-reach sites where HIV hides. All results came back negative for replication-competent virus. No detectable viral RNA or DNA was found. The Oslo patient had also stopped taking ART more than two years before the final testing, and no viral rebound occurred. The study authors concluded he is functionally cured, meaning he is in long-term remission without the need for antiretroviral drugs.

The donor’s CCR5Δ32 mutation was central to the outcome. Globally, only about 3% of people carry this mutation, with the highest frequency in Northern European populations. However, researchers emphasized that the mutation alone does not guarantee a cure. The Oslo patient also experienced mild graft-versus-host disease (GVHD), a condition in which donor immune cells attack the recipient’s tissues. In the context of HIV, this immune assault likely contributed to a “graft-versus-reservoir” effect, destroying any lingering infected cells. Additionally, he received ruxolitinib and vedolizumab, two medications used to manage GVHD that also have demonstrated anti-HIV properties. The convergence of these factors—a resistant donor immune system, an aggressive graft-versus-host response, and pharmacologic help—appears to have sterilized the viral reservoir.

What This Means for You

Stem cell transplantation is an intensive, high-risk procedure with a mortality rate of 10–20% within the first year, primarily due to infections, organ damage, and GVHD. It is reserved for people with life-threatening blood cancers or bone marrow failure, not for treating HIV alone. For the average person living with HIV, daily ART remains the gold standard—it is safe, highly effective, and can reduce the virus to undetectable levels so that transmission risk is zero. If you have HIV, you should not seek a stem cell transplant outside of a clinical trial for a concurrent hematologic disease. Talk openly with your healthcare provider about your treatment goals, but know that a sustainable functional cure for the general population likely lies years away.

The Oslo patient’s case, like those before it, illuminates the biological roadblocks to curing HIV and potential strategies to overcome them. Each success teaches researchers more about how to safely mimic the graft-versus-reservoir effect, how to use gene editing to recapitulate the CCR5Δ32 resistance, and which drugs can flush out latent virus. For now, the practical message is one of hope rooted in science: a cure may be complicated, but it is not impossible.

Expert Perspective

Outside experts described the case as a meaningful step forward. Steven Deeks, MD, professor of medicine at UCSF and a leading HIV researcher who was not involved in the study, noted, “There have now been 10 successful transplants. Each is unique, but they collectively show that there are multiple ways a bone marrow transplant can help cure HIV. We learn from each case.” Augusto Dulanto, MD, an infectious disease specialist at Vanderbilt University, also not part of the research, called the sibling connection “a cause for optimism” and emphasized that the homozygous CCR5Δ32 mutation was key. Marshall Glesby, MD, PhD, of Weill Cornell Medicine, highlighted the interplay of GVHD medications, noting that drugs like ruxolitinib may have independent effects on the HIV reservoir. The study’s chief limitation is its nature as a single case, so the findings cannot be generalized without replication. Further research is needed to confirm whether sibling donors might offer advantages in immune compatibility that enhance the graft-versus-reservoir effect.

Frequently Asked Questions

Q: What is a functional cure for HIV?

A functional cure means that HIV is not completely eradicated from the body, but the virus is controlled to undetectable levels and cannot rebound without ongoing antiretroviral therapy. The person remains healthy, does not develop AIDS, and cannot transmit HIV to others. This differs from a sterilizing cure, in which every trace of the virus is eliminated.

Q: Why does the CCR5Δ32 mutation matter in HIV remission?

HIV typically uses the CCR5 receptor on the surface of immune cells to gain entry. The CCR5Δ32 mutation produces a shortened, non-functional receptor that never reaches the cell surface. When an individual inherits two copies of this mutation (one from each parent), their cells are highly resistant to the most common strains of HIV. Transplanting stem cells with this mutation can effectively rebuild the recipient’s immune system with an inborn shield against the virus.

Q: How many people have been cured of HIV through stem cell transplants?

As of 2026, around ten individuals worldwide have achieved long-term HIV remission following stem cell transplants—most notably the Berlin, London, Düsseldorf, New York, City of Hope, and Geneva patients, as well as the Oslo patient. In most of these cases, the donor had two copies of the CCR5Δ32 mutation, though the Geneva patient is an exception and achieved remission without the mutation, likely through a powerful graft-versus-host response.

Q: Can anyone with HIV get a stem cell transplant to be cured?

No. Stem cell transplants are dangerous, expensive, and ethically justified only for patients who have a life-threatening blood cancer or bone marrow condition that necessitates the procedure. For the general HIV population, antiretroviral therapy is far safer and highly effective. Researchers are actively working on gene therapies and other approaches that could one day deliver a cure without the risks of a transplant.

Q: How long was the Oslo patient monitored before being declared cured?

The Oslo patient was monitored for five years after his transplant, during which he eventually stopped antiretroviral therapy and showed no viral rebound. Extensive testing of his blood, gut tissue, and bone marrow at the five-year mark confirmed no detectable HIV reservoirs, providing strong evidence of a durable functional cure.

Sources

• Nature Microbiology. (2026). Case report on HIV remission after allogeneic hematopoietic stem cell transplantation from a CCR5Δ32 homozygous sibling donor. DOI: 10.1038/s41564-026-02304-8
• Healthline. (2026). Norway Man ‘Likely Cured’ of HIV After Stem Cell Transplant From Brother. (Original news report and expert commentary)